Why BioLife Solutions (BLFS) is on investors’ radar BioLife Solutions (BLFS) has drawn attention after recent share price moves, with the stock up about 21% over the past month and roughly 3% in the ...
Clinical Trial Share -- BioLife products are used in over 250 commercially sponsored cell and gene therapy (CGT) clinical ...
Q1 2026 Management view "We're off to a solid start to 2026 with first quarter revenue growth of 25% and adjusted EBITDA up approximately 15% versus the prior year," said CEO & Chairman Roderick de ...
Reiterated full-year 2026 revenue guidance of $112.5 million to $115 million, assuming 17% to 20% growth based on current customer demand forecasts. Management expects to achieve positive full-year ...
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading ...
BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter. BioLife Solutions said ...
BioLife Plasma, a plasma donation center, opened its 200th U.S. location and first location in Pearland on March 25. The new plasma service center located at 3020 Kirby Drive is part of the ...
The MarketWatch News Department was not involved in the creation of this content. Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth ...
Plasma donation and testing company BioLife Plasma Services LP in has invested $4 million to expand its testing laboratory in Hoover, Ala., and buy equipment to recycle biohazardous plastics waste ...
BioLife CEO Bill Jones calls for a new global health vocabulary, shifting from weight-loss language to biology-driven terms that support metabolic well-being, body positivity, and regenerative care.
BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") ...